A Chinese medicine composition for preventing or treating cognitive decline in the elderly and its application

Abstract

The invention discloses a Chinese medicine composition for preventing or treating cognitive dysfunction in the elderly and an application thereof. Compared with the prior art, the Chinese medicine composition of the invention is composed of wolfberry and calamus which are both medicinal and edible, and has significant effects in treating, alleviating and preventing abnormal cognitive function, especially abnormal cognitive function in the elderly. In comparison with the effects of using wolfberry alone or calamus alone, it can be clearly seen that the combined use of the Chinese medicine composition of the invention has a synergistic effect in the treatment, alleviation and prevention of abnormal cognitive function.

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and relates to a traditional Chinese medicine composition for preventing or treating cognitive decline in the elderly and an application thereof, and specifically relates to wolfberry or its effective component, and Acorus calamus, wherein the effective component of wolfberry is wolfberry polysaccharide. Background Art

[0002] Cognitive decline in the elderly, also known as subjective cognitive decline (SCD), is a cognitive state between intact cognition and objective cognitive impairment. Previous studies have shown that SCD can predict mild cognitive impairment (MCI). Mild cognitive impairment (MCI) refers to people with mild cognitive impairment who have slight cognitive impairment compared to normal elderly people, as reflected in memory, executive function, etc., but cognitive function can function normally.

[0003] Lycium barbarum is mild in nature and sweet in taste. It enters the liver, kidney and lung meridians. The "Ben Jing" records: "Lycium barbarum can cure evil spirits in the five internal organs, thirst caused by heat, rheumatism and arthritis. Long-term use can strengthen muscles and bones, make the body light and not aging, and resist cold and heat." The main ingredients are Lycium barbarum polysaccharide, betaine, and Lycium barbarum pigment. Lycium barbarum polysaccharide is a water-soluble polysaccharide and the main active ingredient in Lycium barbarum, with a relative molecular mass of 68 to 200.

[0004] Acorus gramineus Soland., also known as Golden Money Pu (Acorus gramineus Soland.), is a herbaceous plant of the genus Acorus in the family Acorus. The rhizome of Golden Money Pu is used as medicine. It is pungent, bitter, warm in nature, and can open the mind and resolve phlegm, ward off filth and kill insects. It is mainly used to treat phlegm obstruction, unclear consciousness, chronic tracheitis, dysentery, enteritis, etc. Shennong's Herbal Classic records that Golden Money Pu "treats wind, cold and dampness, cough, reverse breathing, opens the heart, nourishes the five internal organs, clears the nine orifices, brightens the ears and eyes, and produces sound." Summary of the invention

[0005] In order to solve the technical problems existing in the prior art, the present invention provides the following technical solutions:

[0006] The invention provides a traditional Chinese medicine composition, which comprises the following raw materials in parts by weight: 1.67 parts of wolfberry and 0.6 parts of calamus calamus.

[0007] Furthermore, the Chinese medicine composition comprises the following raw materials in parts by weight: 1 part of Lycium barbarum polysaccharide and 12 parts of Acorus calamus.

[0008] In some embodiments, the proportion of Lycium barbarum polysaccharide in Lycium barbarum is 3%. The dosage of Lycium barbarum polysaccharide herein is 50 mg / kg, which is converted to 1.67 g / kg of Lycium barbarum.

[0009] Furthermore, the preparation form of the Chinese medicine composition includes powder, granules, blocks, tablets, capsules, pills, gel candies, water pills, or pastes.

[0010] In some embodiments, the preparation form of the Chinese medicine composition is a powder. In some embodiments, the preparation form of the Chinese medicine composition is a granule. In some embodiments, the preparation form of the Chinese medicine composition is a block. In some embodiments, the preparation form of the Chinese medicine composition is a tablet. In some embodiments, the preparation form of the Chinese medicine composition is a capsule. In some embodiments, the preparation form of the Chinese medicine composition is a pill. In some embodiments, the preparation form of the Chinese medicine composition is a gel candy. In some embodiments, the preparation form of the Chinese medicine composition is a water pill. In some embodiments, the preparation form of the Chinese medicine composition is a paste.

[0011] Furthermore, the types of raw materials include dry medicinal materials, fresh medicinal materials, raw medicinal materials, cooked medicinal materials, processed medicinal materials, the whole plant of medicinal materials, the effective parts of the whole plant of medicinal materials, or a combination thereof.

[0012] In some embodiments, the weight parts are calculated based on the dry weight of the drug substance.

[0013] The "raw material" used in the present invention is synonymous with "raw medicine", which refers to the Chinese medicinal materials that can play the active functions of the present invention. The Chinese medicinal materials include various forms of existence, specifically including dry medicinal materials, fresh medicinal materials, raw medicinal materials, cooked medicinal materials, processed medicinal materials, whole plants of medicinal materials, effective parts of whole plants of medicinal materials, or combinations thereof, but not limited thereto. In some embodiments, the raw materials also include the main active ingredients extracted from the raw materials, and these main active ingredients are all ingredients that have been proven in the prior art.

[0014] Furthermore, the Chinese medicine composition also includes pharmaceutically acceptable excipients.

[0015] Furthermore, the auxiliary materials include adhesives, surfactants, flavoring agents, osmotic pressure regulators, antibacterial agents, stabilizers, and / or solubilizers.

[0016] Furthermore, the binder includes carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, polyethylene glycol, povidone, glycerol, polyvinyl alcohol, polyvinyl pyrrolidone, polyalkyl styrene, polymethacrylate, and / or polyacrylate.

[0017] Further, the surfactant includes hydroxypropyl-β-cyclodextrin, polyoxyethylene alkyl ether, Tween, sodium lauryl sulfate, sodium lauryl sulfate, poloxamer, polysorbate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, and / or polyethylene glycol alkyl.

[0018] Furthermore, the osmotic pressure regulator includes sodium chloride, potassium chloride, mannitol, glycerol, and / or other osmotic pressure regulators acceptable to pharmaceutical or traditional Chinese medicine preparations.

[0019] Further, the antibacterial agent includes BAK, benzalkonium chloride, sorbic acid, oxychlorine complex, citric acid, chlorobutanol, thimerosal, phenylmercuric acetate, disodium edetate, phenylmercuric nitrate, perborate, and / or benzyl alcohol.

[0020] In some embodiments, the excipients may also include substances recognized in the art and including, for example, substances involved in carrying or transporting any of the subject compositions from one organ or part of the body to another organ or part of the body, including, but not limited to: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, ethyl cellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) cocoa butter and suppository waxes; (9) Oils, such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffer; (21) other non-toxic compatible substances used in pharmaceutical preparations.

[0021] In some embodiments, the Chinese medicine composition of the present invention also includes a drug delivery system, specifically including biodegradable polymers, biodegradable implants, non-biodegradable implants, biodegradable microparticles such as biodegradable microspheres, nanoparticles, etc.

[0022] In some embodiments, the usage / dosage of the Chinese medicine composition can be prescribed in a variety of ways depending on factors such as the formulation method, administration method, patient's age, weight, gender, morbidity, diet, administration time, administration route, excretion rate and reaction sensitivity, and such changes can be easily determined and confirmed by physicians skilled in the art.

[0023] In some embodiments, when the Chinese medicine composition of the present invention is administered to a specific individual subject for treatment, the therapeutically effective amount and specific treatment plan for the individual subject may be affected by many factors, including the pharmacodynamic activity of the drug used, the age, weight, general condition, gender, diet, administration time, disease susceptibility, disease progression, and the judgment of the treating physician of the subject. In addition, those skilled in the art are aware that the administration method, dosage form, and dosage of the drug are affected by many factors such as the patient's age, weight, gender, morbidity, diet, administration time, excretion rate, and reaction sensitivity. Therefore, the dosage of the Chinese medicine composition described in the present invention is not limited to the dosage in the embodiments of the present invention, and the same applies to the administration method and dosage form.

[0024] Furthermore, the Chinese medicine composition also includes active ingredients from wolfberry and Acorus calamus or pharmaceutically acceptable salts of the active ingredients.

[0025] Furthermore, the effective ingredients of the wolfberry include wolfberry polysaccharide, betaine and wolfberry pigment.

[0026] Furthermore, the effective ingredients of the Acorus calamus include flavonoid compounds, triterpenoid compounds and phenolic compounds.

[0027] Furthermore, the pharmaceutically acceptable salts include acid addition salts and base addition salts.

[0028] Further, the acid addition salt includes, but is not limited to, any one of the hydrochloride, hydrobromide, hydroiodide, phosphate, sulfate, nitrate, ethanesulfonate, toluenesulfonate, benzenesulfonate, acetate, maleate, tartrate, succinate, citrate, benzoate, ascorbate and salicylate, malonate, adipate, caproate, argininate, fumarate, nicotinate, phthalate or oxalate of FTY720, or a combination of at least two thereof.

[0029] Furthermore, the base addition salt includes but is not limited to lithium salt, sodium salt, potassium salt, barium salt, calcium salt, magnesium salt, aluminum salt, iron salt, ferrous salt, copper salt, zinc salt of FTY720, or a salt of FTY720 with morpholine, diethylamine, triethylamine, isopropylamine, trimethylamine, lysine or histidine.

[0030] The present invention provides the use of the above-mentioned traditional Chinese medicine composition in preparing a product for treating, preventing or alleviating cognitive dysfunction.

[0031] Furthermore, the abnormal cognitive function includes cognitive decline and cognitive dysfunction.

[0032] Furthermore, the cognitive function decline includes cognitive function decline.

[0033] Furthermore, the cognitive decline includes elderly cognitive decline.

[0034] Furthermore, the cognitive dysfunction includes Alzheimer's disease, frontotemporal dementia, vascular dementia, Lewy body dementia, and prion disease.

[0035] Furthermore, the cognitive dysfunction specifically includes abnormal memory, abnormal executive function, abnormal calculation ability, and abnormal attention.

[0036] Furthermore, the memory abnormality includes long-term memory abnormality and short-term memory abnormality.

[0037] In some embodiments, the abnormal cognitive function includes cognitive decline or cognitive dysfunction caused by neurodegenerative diseases. In some embodiments, the neurodegenerative diseases include but are not limited to Parkinson's disease, Huntington's disease, Alzheimer's disease, mild cognitive impairment, senile dementia and amyotrophic lateral sclerosis, spinocerebellar atrophy, Tourette's syndrome, Friedrich's ataxia, Machado-Joseph disease, Lewy body dementia, dystonia, progressive supranuclear palsy, and / or frontotemporal dementia.

[0038] Furthermore, the use of the product has dosage requirements, and the specific dosage requirements are as follows: the weight of the aforementioned Chinese medicine composition with Lycium barbarum polysaccharides and Acorus calamus as raw materials: (0.65g-2g) per kilogram of body weight of the individual: 1kg.

[0039] Further, the specific dosage is the weight of the aforementioned Chinese medicine composition with wolfberry polysaccharide and Acorus calamus as raw materials: 0.65g: 1kg, 0.7g: 1kg, 0.75g: 1kg, 0.8g: 1kg, 0.85g: 1kg, 0.9g: 1kg, 0.95g: 1kg, 1g: 1kg, 1.05g: 1kg, 1.1g: 1kg, 1.15g: 1kg, 1.2g: 1kg. kg, 1.25g: 1kg, 1.3g: 1kg, 1.35g: 1kg, 1.4g: 1kg, 1.45g: 1kg, 1.5g: 1kg, 1.55g: 1kg, 1.6g: 1k g, 1.65g: 1kg, 1.7g: 1kg, 1.75g: 1kg, 1.8g: 1kg, 1.85g: 1kg, 1.9g: 1kg, 1.95g: 1kg, or 2g: 1kg.

[0040] Furthermore, the specific dosage is the weight of the aforementioned traditional Chinese medicine composition with wolfberry polysaccharides and Acorus calamus as raw materials: 0.65g:1kg, 1.3g:1kg, or 2g:1kg per kilogram of body weight of an individual.

[0041] In some embodiments, the aforementioned Chinese medicine composition uses wolfberry and Acorus calamus as raw materials, and the weight ratio of each kilogram of body weight of an individual is converted based on the ratio that wolfberry contains 3% of Lycium barbarum polysaccharide.

[0042] Furthermore, the preparation forms of the product include powder, granules, blocks, tablets, capsules, pills, gel candies, water pills, or pastes.

[0043] In some embodiments, the raw materials in the traditional Chinese medicine composition work together to exert a synergistic effect, and are effective in treating, preventing or alleviating cognitive dysfunction.

[0044] Further, the products include food compositions, including functional foods, nutritional supplements, health foods and food additives.

[0045] In some embodiments, the food composition can be made into tea, juice or beverage, or made into granules, capsules or powder as health food. In some embodiments, the food composition of the present disclosure can also be added to beverages (including alcoholic beverages), fruits and processed products thereof (such as canned fruits, bottled fruits, jams, jams), fish, meat and processed products thereof (such as ham, sausage, corned beef), candies and noodles (such as udon noodles, soba noodles, ramen noodles, pasta, macaroni), juices, beverages, biscuits, Korean toffee, dairy products (such as butter, cheese), vegetable oils, margarines, vegetable proteins, retorted foods, frozen foods, seasonings (such as soybean paste, soy sauce, seasoning sauce), etc. In some embodiments, the food composition of the present invention can include various flavors, natural carbohydrates, etc. as additional ingredients. Carbohydrates are monosaccharides, such as glucose, fructose, etc.; disaccharides, such as maltose and sucrose; polysaccharides, such as dextrin and cyclodextrin; sugar alcohols, such as xylitol, sorbitol, erythritol, etc. Sweeteners may be used, including natural sweeteners such as taurine martin, stevia extract, etc., and synthetic sweeteners such as saccharin, aspartame, etc.

[0046] The present invention provides a method for preparing the above-mentioned traditional Chinese medicine composition, which comprises a process of adding a therapeutically effective amount of raw materials for preparation; the raw materials comprise 1.67 parts of wolfberry and 0.6 parts of calamus tatarinowii.

[0047] Furthermore, the raw material medicine includes 1 part of Lycium barbarum polysaccharide and 12 parts of Acorus calamus.

[0048] The present invention provides the use of wolfberry or wolfberry effective components and Acorus calamus in preparing a traditional Chinese medicine composition for combined treatment, prevention or alleviation of cognitive dysfunction.

[0049] Furthermore, the mass ratio of wolfberry to calamus calamus is 1.67:0.6.

[0050] Furthermore, the effective ingredient of wolfberry is wolfberry polysaccharide.

[0051] Furthermore, the mass ratio of the wolfberry polysaccharide to the Acorus calamus is 1:12.

[0052] Furthermore, the abnormal cognitive function includes cognitive decline and cognitive dysfunction.

[0053] Furthermore, the cognitive function decline includes cognitive function decline.

[0054] Furthermore, the cognitive decline includes elderly cognitive decline.

[0055] Furthermore, the cognitive dysfunction includes Alzheimer's disease, frontotemporal dementia, vascular dementia, Lewy body dementia, and prion disease.

[0056] Furthermore, the cognitive dysfunction specifically includes abnormal memory, abnormal executive function, abnormal calculation ability, and abnormal attention.

[0057] Furthermore, the memory abnormality includes long-term memory abnormality and short-term memory abnormality.

[0058] The present invention provides the use of the above-mentioned traditional Chinese medicine composition in preparing a product for restoring the structure of nerve synapses, increasing the vesicles in the presynaptic membrane of nerves, thickening the thickness of the postsynaptic membrane of nerves, and reducing the degree of damage to mitochondria in nerve cells.

[0059] Furthermore, the neural cells include oligodendrocyte precursor cells, mature oligodendrocytes, neuronal cells, and glial cells.

[0060] In some embodiments, the neural cells are from the brain. In some embodiments, the neural cells are from any animal with clear brain neural tissue. In some embodiments, the neural cells are from the hippocampus. In some embodiments, the neural cells are from mammals. In some embodiments, the neural cells are from humans.

[0061] The term "treatment" used in the present invention includes delaying and stopping the progression of the disease, or eliminating the disease, and does not require 100% inhibition, elimination and reversal. In some embodiments, the Chinese medicine composition of the present invention reduces, inhibits and / or reverses cognitive dysfunction and its complications by, for example, at least about 10%, at least about 30%, at least about 50%, or at least about 80%, compared to the levels observed in the absence of the composition, medicine kit, food box or health product box, active ingredient combination of the present invention.

[0062] The term "prevention" used in the present invention refers to a method of preventing the onset of a disease and / or its attendant symptoms or protecting a subject from acquiring a disease. "Prevention" as used herein also includes delaying the onset of a disease and / or its attendant symptoms and reducing the risk of a subject acquiring a disease.

[0063] The term "parts by weight" as used in the present invention is synonymous with "parts by weight" and refers to any fixed weight expressed in milligrams, grams or kilograms.

[0064] The term "wolfberry" (or "wolfberry") used in the present invention refers to the mature fruit of the deciduous shrub plant Ningxia wolfberry or wolfberry, which is mainly produced in Ningxia, Hebei, Gansu, Qinghai and other places. Wolfberry is flat in nature, sweet in taste, and enters the liver, kidney and lung meridians. It has the effects of nourishing the liver and kidney, improving eyesight, and moistening the lungs. Lycium barbarum polysaccharides rich in wolfberry can promote lipid metabolism; in addition, wolfberry also contains a variety of essential amino acids and vitamins for the human body, which can provide raw materials for the synthesis of proteins in the body and participate in the regulation of sugar metabolism in the body after fatigue. The taurine content is as high as 0.205-0.689wt%, which is currently the only plant reported to contain taurine.

[0065] The term "lycium barbarum polysaccharides" used in the present invention is a water-soluble polysaccharide. It has been confirmed that Lycium barbarum polysaccharides are proteoglycans with a molecular weight of 2225 kD and are composed of six monosaccharide components: arabinose, glucose, acetopolysaccharide, galactose, mannose, xylose, and rhamnose. It is a light yellow powder that is hygroscopic.

[0066] The term "mammal" used in the present invention mainly refers to warm-blooded vertebrate mammals, including but not limited to: cats, dogs, rabbits, bears, foxes, wolves, monkeys, deer, mice, pigs, cows, sheep, horses, humans, etc., preferably primates, and more preferably humans.

[0067] The term "cognitive function" used in the present invention refers to functions such as thinking, reasoning, memory, impression and learning. In some embodiments, the cognition refers to psychological processes including attention, memory, language production and understanding, learning, reasoning, problem solving and decision making.

[0068] The terms "preparation form", "dosage form" and "pharmaceutically acceptable dosage form" used in the present invention are synonymous and all refer to the dosage form of the Chinese medicine composition of the present invention, including, for example: tablets, dragees, powders, elixirs, syrups, liquid preparations, including suspensions, sprays, inhalation tablets, lozenges, emulsions, solutions, granules, capsules and suppositories, as well as liquid preparations for injection, including liposome preparations. These techniques and formulas can generally be found in Remington, "Pharmaceutical Science", Mack Publishing Company, Easton.PA. latest edition.

[0069] The term "pharmaceutically acceptable salt" used in the present invention refers to relatively non-toxic, inorganic or organic acid addition salts and base addition salts of the present invention. These salts can be prepared in situ during the final separation and purification of the compound. Specifically, the purified compound in the form of a free base can be reacted with a suitable organic or inorganic acid, and the salt formed can be separated. See, for example, SM Berge et al., "Pharmaceutically Acceptable Salts", "Journal of Pharmaceutical Sciences", Vol. 66, pp. 1-19 (1997), which is used as a reference here. Base addition salts are prepared by reacting the purified compound in its acid form with a suitable inorganic or organic base, and separating the salt formed in this way.

[0070] The term "neurodegenerative disease" used in the present invention refers to a type of disease in which damage to neurons in the brain and spinal cord gradually worsens over time, with a large loss of specific neurons as the main feature. It is a type of complex disease that progresses and eventually leads to death.

[0071] Advantages and beneficial effects of the present invention:

[0072] The present invention provides a Chinese medicine composition. Compared with the prior art, the Chinese medicine composition has the beneficial effect that the Chinese medicine composition of the present invention is composed of wolfberry and calamus which are both medicinal and edible, and has a significant effect in treating, alleviating and preventing cognitive dysfunction, especially cognitive dysfunction in the elderly. In comparison with the effect of using wolfberry alone or calamus alone, it can be clearly seen that the combined use of the Chinese medicine composition of the present invention has a synergistic effect on the treatment, alleviation and prevention of cognitive dysfunction. BRIEF DESCRIPTION OF THE DRAWINGS

[0073] Figure 1 This is the result of water maze test on the effects of Lycium barbarum polysaccharide, Acorus calamus and the combination of the two on the escape latency of each group of animals, where x±SE, **p<0.01vs young group, #p<0.05, #p<0.01vs old group. n=7;

[0074] Figure 2 This is the result of water maze test on the effects of Lycium barbarum polysaccharide, Acorus calamus and the combination of the two on the total distance traveled by each group of animals, where x±SE, **p<0.01vs young group, #p<0.05, #p<0.01vs old group. n=7;

[0075] Figure 3 This is the statistical result graph of escape latency and total distance of the aged rats + Lycium barbarum polysaccharide treatment group 50mg / kg low-dose group, the aged rats + Acorus calamus treatment group 0.6g / kg low-dose group, and the aged rats + drug combination treatment group, where x±SE;

[0076] Figure 4This is the effect of Lycium barbarum polysaccharide, Acorus calamus and the combination of the same dose on the ultrastructure of hippocampal synapses in aged rats;

[0077] Figure 5 This is the effect of Lycium barbarum polysaccharide, Acorus calamus and the combination of the same dose on the ultrastructure of hippocampal neurons in aged rats;

[0078] Figure 6 This is a graph showing the effects of Lycium barbarum polysaccharides, Acorus calamus and the combination of the two at the same dose on the ultrastructure of mitochondria in the hippocampus of aged rats. DETAILED DESCRIPTION

[0079] Unless otherwise stated, all numbers used in this specification and claims to represent volume, weight, temperature, time, density, weight parts, technical effects, etc. should be understood as being modified by the term "about" or "roughly" in any case. Therefore, unless otherwise indicated, the numerical parameters listed in the following specification and the attached claims are approximate values. Unless otherwise stated, the terms used herein have the usual understanding meanings for those skilled in the art. For those skilled in the art, it can vary according to the desired properties and effects sought to be obtained through the present disclosure, and each numerical parameter should be interpreted according to the number of significant digits and conventional rounding methods or in a manner understood by those skilled in the art.

[0080] The terms used in this application are only used for the purpose of describing specific embodiments and are not to be understood as limiting. As used herein, the singular forms "a" and "an" are also intended to include plural forms, unless the context clearly indicates otherwise. As used herein, the term "and / or" includes any and all combinations of one or more of the relevant enumerated items. Expressions such as "at least one (kind) of ..." modify the entire list of elements when before or after a list of elements, without modifying the individual elements of the list.

[0081] Example 1

[0082] 1. Experimental Materials

[0083] Shanghai Yuanye Biotechnology Co., Ltd.: B26110 Acorus tatarinowii, S31394 Lycium barbarum polysaccharides, S60449 Donepezil hydrochloride.

[0084] 2. Experimental methods

[0085] 2.1 Experimental animals

[0086] Young SD male rats aged 3 months and naturally aged SD male rats aged 20 months were given donepezil as positive control by oral gavage for 4 weeks, and their learning and memory functions were tested by water maze.

[0087] 2.2 Experimental Grouping

[0088] (1) Young rat group: normal saline;

[0089] (2) Aged rat group: normal saline;

[0090] (3) Aged rats + Lycium barbarum polysaccharide treatment group: 50, 100, 200 mg / kg;

[0091] (4) Aged rats + Acorus calamus treatment group: 0.6, 1.2, 1.8 g / kg;

[0092] (5) Aged rats + Lycium barbarum polysaccharide and Acorus calamus combined treatment group (aged rats + drug combined treatment group): Lycium barbarum polysaccharide 50 mg / kg + Acorus calamus 0.6 g / kg;

[0093] (6) Aged rats + donepezil treatment group: 2 mg / kg.

[0094] 2.3 Water maze to test cognitive function

[0095] The water maze consists of a circular pool and an automatic camera and computer analysis system. The camera above the pool synchronously records the movement trajectory of the rat. The water depth is 30 cm and the water temperature is 22-25°C. The animal enters the water with its head facing the pool wall. If it does not find the platform within 60 seconds, it will be led to the platform and left there for more than 10 seconds to guide its learning and memory. The experiment lasted for 5 days, with the first 4 days as training time and the 5th day as testing. Data acquisition and image analysis are completed by the automatic image monitoring and processing system. After the experiment, the escape latency and activity trajectory of each group of animals were recorded.

[0096] 2.4 Transmission electron microscopy

[0097] Detect the ultrastructure of hippocampal synapses, neurons, and mitochondria.

[0098] 3. Experimental results

[0099] 3.1 Effects of Lycium barbarum polysaccharides, Acorus calamus and their combination on cognitive function in elderly rats

[0100] The water maze was used to detect the escape latency of rats to reach the platform. The statistical data are shown in Table 1. The results showed that compared with the young rat group, the escape latency and total distance of the old rat group were significantly increased; compared with the old rat group, the old rats + Lycium barbarum polysaccharide treatment group (50, 100, 200 mg / kg low, medium and high doses), the old rats + Acorus tatarinowii treatment group (0.6, 1.2, 1.8 g / kg low, medium and high doses) and the old rats + Lycium barbarum polysaccharide Acorus tatarinowii combined treatment group, the escape latency ( Figure 1 ) and total distance ( Figure 2 ) was significantly reduced.

[0101] Table 1 Effects of Lycium barbarum polysaccharides, Acorus calamus and their combination on cognitive function in elderly rats

[0102]

[0103] Subsequently, we analyzed the data of the aged rats + Lycium barbarum polysaccharide treatment group (50 mg / kg low dose), the aged rats + Acorus tatarinowii treatment group (0.6 g / kg low dose), and the aged rats + drug combination treatment group, and found that the efficacy of the aged rats + drug combination treatment group was significantly different from that of the single drug (aged rats + Lycium barbarum polysaccharide treatment group, aged rats + Acorus tatarinowii treatment group) ( Figure 3 ).

[0104] 3.2 Effects of Lycium barbarum polysaccharides, Acorus tatarinowii, and their combination on the ultrastructure of hippocampal synapses in aged rats

[0105] The synaptic structure of the young rat group was complete, with a large number of synaptic vesicles visible before the synapse, a clear synaptic cleft, and a large number of electron-dense substances around the synapse; the synaptic structure of the old rat group was unclear, the synaptic cleft was unclear, and there were fewer synaptic vesicles; compared with the old rat group, after combined intervention in the old rat + low-dose Lycium barbarum polysaccharide treatment group, the old rat + low-dose Acorus tatarinowii treatment group, and the old rat + drug combination treatment group, it can be seen that the synaptic structure is relatively complete, the synaptic cleft and the boundaries between the presynaptic and postsynaptic membranes are clear, there are more vesicles in the presynaptic membrane, and the postsynaptic membrane is uniformly thickened ( Figure 4 ).

[0106] 3.3 Effects of Lycium barbarum polysaccharides, Acorus tatarinowii, and their combination on the ultrastructure of hippocampal neurons in aged rats

[0107] The hippocampal neuron cell bodies of the young rats were large and intact, with smooth nucleus edges and evenly distributed chromatin; the hippocampal neuron structures of the old rats were damaged, with shrunken nuclei and condensed chromatin, and lysosomes formed in the cytoplasm. Compared with the old rats, the symptoms of ultrastructural damage to the hippocampal neurons in the old rats + low-dose Lycium barbarum polysaccharide treatment group, the old rats + low-dose Acorus tatarinowii treatment group, and the old rats + drug combination treatment group were alleviated after combined intervention ( Figure 5 ).

[0108] 3.4 Effects of Lycium barbarum polysaccharides, Acorus tatarinowii, and their combination on the ultrastructure of mitochondria in the hippocampus of aged rats

[0109] The hippocampal mitochondrial structure of the young rats was intact, and the mitochondrial membrane and cristae were normal; the hippocampal mitochondrial structure of the old rats was damaged, and mitochondrial cristae were swollen and broken; compared with the old rats, the symptoms of mitochondrial ultrastructure damage were alleviated after combined intervention in the old rats + low-dose Lycium barbarum polysaccharide treatment group, the old rats + low-dose Acorus tatarinowii treatment group, and the old rats + drug combination treatment group ( Figure 6 ).

[0110] The description of the above embodiments is only used to understand the method and core idea of ​​the present invention. It should be pointed out that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.

Claims

1. A traditional Chinese medicine composition for treating cognitive decline in the elderly, the traditional Chinese medicine composition is composed of the following raw materials in parts by weight: 1 part of wolfberry polysaccharide and 12 parts of calamus tatarinowii.

2. The Chinese medicine composition for treating cognitive decline in the elderly according to claim 1, wherein the preparation form of the Chinese medicine composition includes powder, granules, blocks, tablets, capsules, pills, gel candies, or pastes.

3. The Chinese medicine composition for treating cognitive decline in the elderly according to claim 1, wherein the preparation form of the Chinese medicine composition comprises water pills.

4. The Chinese medicine composition for treating cognitive decline in the elderly according to claim 1, further comprising a pharmaceutically acceptable excipient.

5. The Chinese medicine composition for treating cognitive decline in the elderly according to claim 4, wherein the auxiliary materials include a binder, a surfactant, a flavoring agent, an osmotic pressure regulator, an antibacterial agent, a stabilizer, and / or a solubilizer.

6. Use of the Chinese medicine composition for treating cognitive decline in the elderly according to any one of claims 1 to 5 in the preparation of a medicament for treating, preventing or alleviating cognitive decline in the elderly.

7. The use according to claim 6, wherein the specific dosage requirement of the drug is the weight of Lycium barbarum polysaccharide and Acorus calamus as raw materials: (0.65g-2g) per kilogram of body weight of an individual: 1 kg.

8. The use according to claim 7, wherein the specific dosage is the weight of Lycium barbarum polysaccharide and Acorus calamus as raw materials: 0.65g: 1kg, 0.7g: 1kg, 0.75g: 1kg, 0.8g: 1kg, 0.85g: 1kg, 0.9g: 1kg, 0.95g: 1kg, 1g: 1kg, 1.05g: 1kg, 1.1g: 1kg, 1.15g: 1kg, 1.2g: 1kg, 1.25g: 1kg, 1.3g: 1kg, 1.35g: 1kg, 1.4g: 1kg, 1.45g: 1kg, 1.5g: 1kg, 1.55g: 1kg, 1.6g: 1 kg, 1.65g: 1kg, 1.7g: 1kg, 1.75g: 1kg, 1.8g: 1kg, 1.85g: 1kg, 1.9g: 1kg, 1.95g: 1kg, or 2g: 1kg.

9. The use according to claim 7, wherein the specific dosage is the weight of Lycium barbarum polysaccharide and Acorus calamus as raw materials: 0.65g:1kg, 1.3g:1kg, or 2g:1kg per kilogram of body weight of an individual.

10. A method for preparing the Chinese medicine composition for treating cognitive decline in the elderly as described in any one of claims 1-5, the method comprising a process of adding a therapeutically effective amount of raw materials for preparation; the raw materials are 1 part of wolfberry polysaccharides and 12 parts of Acorus calamus.

Images